Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Carcinoma, Renal Cell 65Neoplasms 10Neoplasm Metastasis 9Kidney Neoplasms 7Prostatic Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Clear-cell metastatic renal cell carcinoma 4Breast Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 2Financial Stress 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Patient Preference 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Oncocytoma, renal 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Lung Neoplasms 1Liver Neoplasms 1

Interventions

Filgrastim 9Cyclophosphamide 9X-Rays 7Phantoms, Imaging 7Specimen Handling 6Magnetic Resonance Spectroscopy 6Flow Cytometry 6Carboplatin 6Temozolomide 5Nuclear Medicine Department, Hospital 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Busulfan 5Biopsy 5Therapeutics 4Polymerase Chain Reaction 4Peripheral Blood Stem Cell Transplantation 4Etoposide 4Amplified Fragment Length Polymorphism Analysis 4fludarabine 3Vincristine 3Topotecan 3Thiotepa 3Stem Cell Transplantation 3Psychiatric Rehabilitation 3Methylprednisolone 3Itraconazole 3Irinotecan 3Ipilimumab 3Immunologic Techniques 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × pazopanib × Genitourinary × Clear all
NCT01130623 2017-07-02

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡